Radioimmunotherapy in follicular lymphoma

Tim Illidge, Franck Morschhauser

    Research output: Contribution to journalArticlepeer-review


    The exquisite sensitivity of haematological malignancies to targeted radiation make Radioimmunotherapy (RIT) a theoretically attractive therapeutic approach. Furthermore, impressive results initially achieved by the pioneers in this field and more recently in larger studies have demonstrated the high clinical activity of RIT in follicular NHL (FL). For more than a decade clinical RIT of FL has been dominated by targeting the CD20 antigen and a number of pivotal clinical studies have resulted in the approval by the US FDA (Food and Drug Administration) of two radioimmunconjugates, 131I-tositumomab (Bexxar) and 90Y-ibritumomab (Zevalin). 90Y-ibritumomab tiuxetan was subsequently approved within the EU in 2004 and more recently in the EU and in the US as a front line "consolidation" treatment in follicular NHL. Recent data have demonstrated that fractionated radioimmunotherapy targeting CD22 with 90Y-epratuzumab tetraxetan achieved a high degree of durable complete responses in relapsed/refractory NHL. Despite the fact that these RIT agents clearly have unique non-cross reactive mechanisms of action with proven high clinical efficacy in patients resistant to both chemotherapy and rituximab, they have not been widely adopted by haemato-oncology community to date. This chapter reviews the progress that has been made in the development of clinical radioimmunotherapy in follicular lymphoma and suggest some guidelines to use it appropriately in first-line but also in the increasing number of patients emerging who are rituximab-refractory. © 2011 Elsevier Ltd. All rights reserved.
    Original languageEnglish
    Pages (from-to)279-293
    Number of pages14
    JournalBest Practice and Research: Clinical Haematology
    Issue number2
    Publication statusPublished - Jun 2011


    • Anti CD20
    • Follicular Lymphoma
    • Monoclonal Antibody
    • Radioimmunotherapy


    Dive into the research topics of 'Radioimmunotherapy in follicular lymphoma'. Together they form a unique fingerprint.

    Cite this